From network prediction to in vivo validation: luteolin attenuates cholestatic liver injury in association with PI3K/Akt/GSK-3β signalling modulation
Naunyn-Schmiedeberg's Archives of Pharmacology · 2026
DOI: 10.1007/s00210-026-05577-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2026. Verfasst von Yuxin Wu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Baotou Central Hospital, Baotou, 014040, Inner Mongolia Autonomous Region, China. Hauptthemen laut MEDLINE: Luteolin, Glycogen Synthase Kinase 3 beta, Proto-Oncogene Proteins c-akt, Phosphatidylinositol 3-Kinases. Die Arbeit nennt 41 Literaturangaben. Gefördert von: Natural Science Foundation of Inner Mongolia Autonomous Region.
Abstract (Originalsprache)
Cholestatic liver disease (CLD) is characterized by inflammatory amplification, hepatic stellate cell activation and collagen deposition. Luteolin is a natural flavonoid with reported anti-inflammatory and anti-fibrotic activities. Here, network pharmacology, molecular docking and experimental analyses were integrated to examine the effects of luteolin in CLD, with a focus on PI3K/Akt/GSK-3β-associated signalling. Target prediction identified 181 putative luteolin targets and 4,403 CLD-related targets, with 88 overlapping genes. In a bile duct ligation (BDL) rat model, luteolin treatment was associated with lower serum injury indices, reduced histopathological damage, decreased collagen deposition and lower fibrosis-related readouts. Experimental analyses further showed that luteolin treatment was accompanied by lower phosphorylation-associated readouts along the PI3K/Akt/GSK-3β axis. Together, these findings support an association between luteolin treatment and attenuation of cholestatic liver injury and fibrosis, within a multi-target signalling context that includes PI3K/Akt/GSK-3β.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, Baotou Central Hospital, Baotou, 014040, Inner Mongolia Autonomous Region, China.
- Baotou Medical College, Baotou, 014040, Inner Mongolia Autonomous Region, China.
- Department of Human Anatomy, Baotou Medical College, Baotou, 014040, Inner Mongolia Autonomous Region, China.
- Key Laboratory of Human Anatomy, Education Department of Inner Mongolia Autonomous Region, Baotou, 014040, Inner Mongolia Autonomous Region, China.
- Department of General Surgery, Baotou Central Hospital, Baotou, 014040, Inner Mongolia Autonomous Region, China. dongming721@163.com.
- Department of Human Anatomy, Baotou Medical College, Baotou, 014040, Inner Mongolia Autonomous Region, China. jiajianxindx@163.com.
Förderung
- Natural Science Foundation of Inner Mongolia Autonomous Region
Zitieren
APA
Wu, Y., Gong, S., Wu, X., Wang, W., Zhang, D., & Jia, J. (2026). From network prediction to in vivo validation: luteolin attenuates cholestatic liver injury in association with PI3K/Akt/GSK-3β signalling modulation. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-026-05577-2
Vancouver
Wu Y, Gong S, Wu X, Wang W, Zhang D, Jia J. From network prediction to in vivo validation: luteolin attenuates cholestatic liver injury in association with PI3K/Akt/GSK-3β signalling modulation. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026. doi:10.1007/s00210-026-05577-2
BibTeX
@article{Wu2026,
author = {Wu, Yuxin and Gong, Shiji and Wu, Xin and Wang, Wei and Zhang, Dongming and Jia, Jianxin},
title = {From network prediction to in vivo validation: luteolin attenuates cholestatic liver injury in association with PI3K/Akt/GSK-3β signalling modulation},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2026},
doi = {10.1007/s00210-026-05577-2}
}
EUVIMED